Deaths from many types of Cancer associated with low vitamin D- review of meta-analyses Sept 2020

Vitamin D and Clinical Cancer Outcomes: A Review of Meta-Analyses

JBMR Plushttps://doi.org/10.1002/jbm4.10420
John D Sluyter,1 ©JoAnn E Manson,2,3 and Robert Scragg1 ®

  • 1School of Population Health, University of Auckland, Auckland, New Zealand
  • 2Department of Medicine, Brigham and Women;s Hospital, and Harvard Medical School, Boston, MA, USA
  • 3Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
VitaminDWiki

Note: This umbrella review appears to assume Cancer deaths due to low vitamin D getting to cells only occur when vitamin D levels are less than 30 ng. This ignores cancer deaths at higer levels of vitamin D for some cancers and ignores cancer deaths when Vitamin D is limited in getting to cells - by genes, etc.
Cancers get less Vitamin D when there is a poor Vitamin D Receptor

The Meta-analysis of CANCER and Vitamin D

The Meta-analysis of Breast Cancer and Vitamin D

The Meta-analysis of Bladder Cancer and Vitamin D

The Meta-analysis of Colon Cancer and Vitamin D

The Meta-analysis of Prostate Cancer and Vitamin D


 Download the PDF from VitaminDWiki

The relationship between vitamin D status or supplementation and cancer outcomes has been examined in several meta-analyses.To address remaining knowledge gaps, we conducted a systematic overview and critical appraisal of pertinent meta-analyses. For metaanalyses of trials, we assessed their quality using AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews), strength of associations using umbrella review methodology and credibility of evidence using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) criteria. Meta-analyses of observational studies reported inverse associations of 25OHD with risk of cancer incidence and cancer mortality and, particularly for colorectal cancer, fulfilled some of Bradford-Hill7s causation criteria. In meta-analyses of trials, vitamin D supplementation did not affect cancer incidence. However, we found credible evidence that vitamin D supplementation reduced total cancer mortality risk, with five out of six meta-analyses reporting a relative risk (RR) reduction of up to 16%: RR, 0.84 (95% CI, 0.74-0.95). The strength of the association, however, was classified as weak. This was true among metaanalyses of high, moderate, and lower quality (AMSTAR-2-rated). Trials did not include large numbers of vitamin D-deficient participants; many tested relatively low doses and lacked sufficiently powered data on site-specific cancers. In conclusion, meta-analyses show that, although observational evidence indicates that low vitamin D status is associated with a higher risk of cancer outcomes, randomized trials show that vitamin D supplementation reduces total cancer mortality, but not cancer incidence. However, trials with larger proportions of vitamin D-insufficient participants and longer durations of follow-up, plus adequately powered data on site- specific common cancers, would provide further insight into the evidence base.

  • © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

4077 visitors, last modified 31 Dec, 2020,
Printer Friendly Follow this page for updates